You are here: Industry Insights > Takeda Pharmaceutical

News List

Breaking News! The Second ADC Approved for Marketing in China PharmaSources/Xiaoyaowan
May 21, 2020
According to the NMPA website on May 13, the marketing application for Brentuximab Vedotin Injection filed by Takeda Pharmaceutical in China has been reviewed and approved, to become the second ADC approved for marketing in China.
Double digit MCap growth in 2019 for 14 of top 20 pharma companies: GlobalData expresspharma
June 19, 2020
Among the positive performances were Takeda Pharmaceutical and Daiichi Sankyo, which reported more than 100 per cent YoY growth in their market caps.
Takeda gets expanded EC approval for lymphoma drug Adcetris pharmaceutical-business-review
May 19, 2020
Takeda Pharmaceutical has secured expanded approval from the European Commission (EC) for its Adcetris in combination with CHP (cyclophosphamide, doxorubicin, prednisone).
Takeda gets EU approval for ALUNBRIG in ALK+ NSCLC pharmaceutical-business-review
April 09, 2020
Takeda Pharmaceutical has secured expanded approval for ALUNBRIG (brigatinib) in the European Union (EU) to use the tyrosine kinase inhibitor for the treatment of a particular lung cancer population.
Takeda teams up with plasma firms for Covid-19 hyperimmune therapy pharmaceutical-technology
April 08, 2020
Takeda Pharmaceutical and its partner CSL Behring have teamed up with plasma companies Biotest, BPL, LFB and Octapharma to develop a hyperimmune therapy for Covid-19.
Takeda enters rare disease alliance with Evox Therapeutics pharmaceutical-technology
March 30, 2020
Takeda Pharmaceutical has entered a multi-target alliance with biotechnology company Evox Therapeutics to develop protein replacement and mRNA therapies for rare diseases.
Takeda initiates development of a plasma-derived therapy for COVID-19 expresspharma
March 05, 2020
Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) being developed to treat infected, high-risk individuals with COVID-19.
Takeda to sell select non-core assets in Latin America for $825m pharmaceutical-technology
March 04, 2020
Takeda Pharmaceutical has agreed to sell a portfolio of select non-core products exclusively in Latin America to Brazilian firm Hypera Pharma for $825m.
Takeda takes step towards EU Entyvio extension biospectrumasia
April 03, 2019
European Medicines Agency accepts Takeda’s Marketing Authorization Application for a subcutaneous formulation of Vedolizumab for maintenance therapy in moderately to severely active Ulcerative Colitis and Crohn’s Disease
Petra Pharma announces licensing agreement with Takeda Pharmaceutical Company pharmafocusasia
March 21, 2019
Petra Pharma Corporation ("Petra"), a leader in phosphoinositide (PI) signaling pathway inhibition, announced it has secured a global license from Takeda Pharmaceutical Company Limited ("Takeda") to develop, manufacture and commercialize serabelisib and t

Previous page 1 2 Next page